|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Langer CJ, Mok T and Postmus PE: Targeted
agents in the third-/fourth-line treatment of patients with
advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer
Treat Rev. 39:252–260. 2013. View Article : Google Scholar
|
|
3
|
de Boer RH, Arrieta Ó, Yang CH, Gottfried
M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH,
et al: Vandetanib plus pemetrexed for the second-line treatment of
advanced non-small-cell lung cancer: A randomized, double-blind
phase III trial. J Clin Oncol. 29:1067–1074. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Rourke N, Roqué I, Figuls M, Farré
Bernadó N and Macbeth F: Concurrent chemoradiotherapy in non-small
cell lung cancer. Cochrane Database Syst Rev.
6:CD0021402010.PubMed/NCBI
|
|
5
|
Barr MP, Gray SG, Hoffmann AC, Hilger RA,
Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ and
O'Byrne KJ: Generation and characterisation of cisplatin-resistant
non-small cell lung cancer cell lines displaying a stem-like
signature. PLoS One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Einhorn LH: First-line chemotherapy for
non-small-cell lung cancer: Is there a superior regimen based on
histology? J Clin Oncol. 26:3485–3486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rossi A, Di Maio M, Chiodini P, Rudd RM,
Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, et al:
Carboplatin- or cisplatin-based chemotherapy in first-line
treatment of small-cell lung cancer: The COCIS meta-analysis of
individual patient data. J Clin Oncol. 30:1692–1698. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
9
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Basu A and Krishnamurthy S: Cellular
responses to Cisplatin-induced DNA damage. J Nucleic Acids.
2010:2013672010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Friedberg EC, Lehmann AR and Fuchs RP:
Trading places: How do DNA polymerases switch during translesion
DNA synthesis? Mol Cell. 18:499–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gan GN, Wittschieben JP, Wittschieben BØ
and Wood RD: DNA polymerase zeta (pol zeta) in higher eukaryotes.
Cell Res. 18:174–183. 2008. View Article : Google Scholar
|
|
15
|
Okada T, Sonoda E, Yoshimura M, Kawano Y,
Saya H, Kohzaki M and Takeda S: Multiple roles of vertebrate REV
genes in DNA repair and recombination. Mol Cell Biol. 25:6103–6111.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen X, Jun S, O'Neal LE, Sonoda E, Bemark
M, Sale JE and Li L: REV3 and REV1 play major roles in
recombination-independent repair of DNA interstrand cross-links
mediated by monoubiquitinated proliferating cell nuclear antigen
(PCNA). J Biol Chem. 281:13869–13872. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wittschieben JP, Reshmi SC, Gollin SM and
Wood RD: Loss of DNA polymerase zeta causes chromosomal instability
in mammalian cells. Cancer Res. 66:134–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan Q, Fang Y, Xu Y, Zhang K and Hu X:
Down-regulation of DNA polymerases kappa, eta, iota, and zeta in
human lung, stomach, and colorectal cancers. Cancer Lett.
217:139–147. 2005. View Article : Google Scholar
|
|
19
|
Zhang S, Chen H, Zhao X, Cao J, Tong J, Lu
J, Wu W, Shen H, Wei Q and Lu D: REV3L 3′UTR 460 T>C
polymorphism in microRNA target sites contributes to lung cancer
susceptibility. Oncogene. 32:242–250. 2013. View Article : Google Scholar
|
|
20
|
Lin X, Trang J, Okuda T and Howell SB: DNA
polymerase zeta accounts for the reduced cytotoxicity and enhanced
mutagenicity of cisplatin in human colon carcinoma cells that have
lost DNA mismatch repair. Clin Cancer Res. 12:563–568. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eastman A, Jennerwein MM and Nagel DL:
Characterization of bifunctional adducts produced in DNA by
transdiamminedichloroplatinum(II). Chem Biol Interact. 67:71–80.
1988. View Article : Google Scholar
|
|
22
|
Zhang S, Lu J, Zhao X, Wu W, Wang H, Lu J,
Wu Q, Chen X, Fan W, Chen H, et al: A variant in the CHEK2 promoter
at a methylation site relieves transcriptional repression and
confers reduced risk of lung cancer. Carcinogenesis. 31:1251–1258.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jamieson ER and Lippard SJ: Structure,
recognition, and processing of cisplatin-DNA adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar
|
|
24
|
Nojima K, Hochegger H, Saberi A, Fukushima
T, Kikuchi K, Yoshimura M, Orelli BJ, Bishop DK, Hirano S, Ohzeki
M, et al: Multiple repair pathways mediate tolerance to
chemotherapeutic cross-linking agents in vertebrate cells. Cancer
Res. 65:11704–11711. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lange SS, Takata K and Wood RD: DNA
polymerases and cancer. Nat Rev Cancer. 11:96–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Albertella MR, Green CM, Lehmann AR and
O'Connor MJ: A role for polymerase eta in the cellular tolerance to
cisplatin-induced damage. Cancer Res. 65:9799–9806. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alt A, Lammens K, Chiocchini C, Lammens A,
Pieck JC, Kuch D, Hopfner KP and Carell T: Bypass of DNA lesions
generated during anticancer treatment with cisplatin by DNA
polymerase eta. Science. 318:967–970. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu F, Lin X, Okuda T and Howell SB: DNA
polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and
the rate of development of cisplatin resistance. Cancer Res.
64:8029–8035. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Okuda T, Lin X, Trang J and Howell SB:
Suppression of hREV1 expression reduces the rate at which human
ovarian carcinoma cells acquire resistance to cisplatin. Mol
Pharmacol. 67:1852–1860. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin X, Okuda T, Trang J and Howell SB:
Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin
in human ovarian carcinoma cells. Mol Pharmacol. 69:1748–1754.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheung HW, Chun AC, Wang Q, Deng W, Hu L,
Guan XY, Nicholls JM, Ling MT, Chuan Wong Y, Tsao SW, et al:
Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads
to chemosensitization to DNA-damaging agents. Cancer Res.
66:4357–4367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Zhang SY, Wang S, Lu J, Wu W, Weng
L, Chen D, Zhang Y, Lu Z, Yang J, et al: REV3L confers
chemoresistance to cisplatin in human gliomas: The potential of its
RNAi for synergistic therapy. Neurooncol. 11:790–802. 2009.
|
|
33
|
Tan NY and Khachigian LM: Sp1
phosphorylation and its regulation of gene transcription. Mol Cell
Biol. 29:2483–2488. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fojas de Borja P, Collins NK, Du P,
Azizkhan-Clifford J and Mudryj M: Cyclin A-CDK phosphorylates Sp1
and enhances Sp1-mediated transcription. EMBO J. 20:5737–5747.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iwahori S, Yasui Y, Kudoh A, Sato Y,
Nakayama S, Murata T, Isomura H and Tsurumi T: Identification of
phosphorylation sites on transcription factor Sp1 in response to
DNA damage and its accumulation at damaged sites. Cell Signal.
20:1795–1803. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ryu H, Lee J, Zaman K, Kubilis J, Ferrante
RJ, Ross BD, Neve R and Ratan RR: Sp1 and Sp3 are oxidative
stress-inducible, antideath transcription factors in cortical
neurons. J Neurosci. 23:3597–3606. 2003.PubMed/NCBI
|
|
37
|
Meighan-Mantha RL, Riegel AT, Suy S,
Harris V, Wang FH, Lozano C, Whiteside TL and Kasid U: Ionizing
radiation stimulates octamer factor DNA binding activity in human
carcinoma cells. Mol Cell Biochem. 199:209–215. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grande L, Bretones G, Rosa-Garrido M,
Garrido-Martin EM, Hernandez T, Fraile S, Botella L, de Alava E,
Vidal A, Garcia del Muro X, et al: Transcription factors Sp1 and
p73 control the expression of the proapoptotic protein NOXA in the
response of testicular embryonal carcinoma cells to cisplatin. J
Biol Chem. 287:26495–26505. 2012. View Article : Google Scholar : PubMed/NCBI
|
